Instrument Inactif

Autres langues AgeX Therapeutics, Inc.

Actions

AGE

US00848H2076

Autres langues

26/03/24	Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
22/03/24	AgeX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
22/03/24	AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results
27/02/24	AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
11/01/24	AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee
28/12/23	AgeX Therapeutics : New Financial Obligation - Form 8-K
01/12/23	AgeX Therapeutics : Termination of Material Agreement - Form 8-K
17/11/23	Pfizer Signs License Agreement With Serina Therapeutics to Gain Access to POZ Polymer Technology
14/11/23	Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q3 Revenue $67,000
14/11/23	AgeX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
14/11/23	AgeX Therapeutics Reports Third Quarter 2023 Financial Results
06/10/23	AgeX Therapeutics : New Financial Obligation - Form 8-K
08/09/23	AgeX Therapeutics, Inc. Announces Departure of Dr. Michael H. May as Director of the Company
06/09/23	AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
30/08/23	Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
30/08/23	Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. from shareholders in a reverse merger transaction.
25/08/23	AgeX Therapeutics : New Financial Obligation - Form 8-K
14/08/23	Earnings Flash (AGE) AGEX THERAPEUTICS Posts Q2 Revenue $9,000
14/08/23	AgeX Therapeutics, Inc. Announces CEO Changes
14/08/23	Agex Therapeutics, Inc. Appoints Jean-Christophe Renondin on the Board of Directors, and Member of Audit Committee, Compensation Committee, and as Chair of the Nominating and Corporate Governance Committee
14/08/23	AgeX Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
14/08/23	AgeX Therapeutics Reports Second Quarter 2023 Financial Results
25/07/23	AgeX Therapeutics Issues Preferred Shares to Juvenescence in Exchange for Debt Cancellation
25/07/23	AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
24/07/23	AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock